Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...
Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its ...
Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...
Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...
Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company ...
Joe Jimenez's Aditum Bio, an investment firm that builds companies around in-licensed assets, is going after one of the hottest new areas for its latest startup. The Oakland, CA-based firm ...
Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an ...
After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...
Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback